Impact of Liraglutide to Semaglutide Conversion on Glycemic Control and Cost Savings at a Veterans Affairs Medical Center.

Background: Semaglutide and liraglutide are glucagon-like peptide 1 receptor agonists (GLP-1 RAs) approved by the US Food and Drug Administration for patients with type II diabetes mellitus (T2DM). Patients with T2DM treated with liraglutide at the Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC) were converted to semaglutide.

Burnt Out? The Phenomenon of Type 2 Diabetes Mellitus in End-Stage Renal Disease.

In patients with T2DM and ESRD, insulin is the antidiabetic medication of choice with a hemoglobin A target of 6 to 8%, using fructosamine levels or other measures for better assessment of glycemic control.

Impact of Point-of-Care Implementation in Pharmacist-Run Anticoagulation Clinics Within a Community-Owned Health System: A Two-Year Retrospective Analysis.

Background: Point-of-care (POC) testing devices allow laboratory monitoring to be performed in various settings and accessed immediately.

Objective: To evaluate the outcomes of monitoring anticoagulation patients in pharmacistmanaged, multicenter clinics utilizing i-STAT POC machines.

Methods: This study was a retrospective, multicenter chart review of 150 patients before and after implementation of the POC intervention for anticoagulation monitoring.